In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170)
- PMID: 18725461
- PMCID: PMC2719004
- DOI: 10.1215/15228517-2008-055
In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170)
Comment on
-
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.Neuro Oncol. 2008 Apr;10(2):162-70. doi: 10.1215/15228517-2007-062. Epub 2008 Mar 4. Neuro Oncol. 2008. PMID: 18356283 Free PMC article.
References
-
- Meyers C, Brown P. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24:1305–1309. - PubMed
-
- Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157–165. - PubMed
-
- Sherman AM, Jaeckle K, Meyers CA. Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer. 2002;15:1311–1316. - PubMed
-
- Meyers CA, Hess KR, Yung WKA, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18:646–650. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
